This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Thomas, M. et al. Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases. Rheumatology https://doi.org/10.1093/rheumatology/kead449 (2023)
Related article
Grainger, R. et al. COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nat. Rev. Rheumatol. 18, 191–204 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Onuora, S. Pre-exposure prophylaxis reduces risk of COVID-19. Nat Rev Rheumatol 19, 677 (2023). https://doi.org/10.1038/s41584-023-01039-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-023-01039-8